Table 3 Baseline Characteristics of Patients with Chronic Subdural Hematoma according to postoperative BUN quartile
Variables | BUN quartiles | ||||
|---|---|---|---|---|---|
quartile 1 n = 170(≤4.0) | quartile 2 n = 162(> 4.0,≤4.9) | quartile 3 n = 164(> 4.9,≤6.4) | quartile 4 n = 157(> 6.4) | P-value | |
BUN (mmol/L) | 3.4 (3.0,3.7) | 4.5 (4.3,4.8) | 5.7 (5.3,6.0) | 7.4 (6.9,8.3) | < 0.001 |
Demographic parameters | |||||
Age (years) | 68 (61,76) | 72 (63,79) | 73 (66,82) | 76 (69,83) | < 0.001 |
Gender, male, n (%) | 140 (82.4%) | 148 (91.4%) | 141 (86.0%) | 132 (84.1%) | 0.103 |
Current drinking, n (%) | 61 (35.9%) | 62 (38.3%) | 58 (35.4%) | 53 (33.8%) | 0.866 |
Current smoking, n (%) | 68 (39.4%) | 56 (34.6%) | 63 (38.4%) | 51 (32.5%) | 0.526 |
Baseline SBP (mmHg) | 138.4 ± 19.4 | 139.3 ± 19.7 | 141.0 ± 20.6 | 142.5 ± 21.0 | 0.274 |
Baseline DBP (mmHg) | 79 (71,87) | 79 (73,86) | 77 (72,88) | 78 (71,87) | 0.984 |
Laboratory investigation | |||||
Blood glucose (mmol/L) | 5.5 (4.8,6.5) | 5.6 (4.7,6.6) | 5.6 (4.7,6.8) | 5.4 (4.5,6.7) | 0.818 |
Cr (μmol/L) | 60 (54,68) | 66 (57,75) | 69 (60,80) | 74 (63,87) | < 0.001 |
Leukocyte (X10^9/L) | 7.00 (6.14,8.45) | 6.97 (5.81,8.62) | 6.98 (5.73,8.33) | 6.77 (5.55,8.39) | 0.677 |
Neutrophil (X10^9/L) | 4.78 (3.84,6.31) | 4.68 (3.76,6.30) | 4.52 (3.59,5.92) | 4.52 (3.60,5.95) | 0.369 |
Lymphocyte (X10^9/L) | 1.50 (1.10,1.80) | 1.40 (1.10,1.71) | 1.50 (1.11,1.87) | 1.45 (1.10,1.81) | 0.518 |
Erythrocyte (X10^12/L) | 4.30 ± 0.51 | 4.27 ± 0.50 | 4.24 ± 0.52 | 4.12 ± 0.52 | 0.008 |
Hemoglobin (g/L) | 133 (120,144) | 133 (123,142) | 132 (120,144) | 130 (116,139) | 0.047 |
Platelet (X10^9/L) | 219 (174,259) | 206 (175,250) | 203 (175,243) | 201 (162,249) | 0.183 |
Prothrombin Time (s) | 13.3 (12.7,13.8) | 13.2 (12.9,13.9) | 13.4 (12.9,13.9) | 13.4 (12.9,14.1) | 0.523 |
INR | 1.02 (0.97,1.07) | 1.02 (0.97,1.08) | 1.03 (0.97,1.08) | 1.03 (0.97,1.10) | 0.484 |
Fibrinogen (g/L) | 3.55 (3.11,4.38) | 3.71 (3.10,4.35) | 3.61 (2.97,4.18) | 3.67 (3.12,4.26) | 0.740 |
Comorbidities | |||||
Hypertension, n (%) | 61 (35.9%) | 61 (37.7%) | 60 (36.6%) | 70 (44.6%) | 0.355 |
Diabetes mellitus, n (%) | 18 (10.6%) | 18 (11.1%) | 17 (10.4%) | 24 (15.3%) | 0.480 |
Cardiovascular disease, n (%) | 9 (5.3%) | 10 (6.2%) | 11 (6.7%) | 12 (7.6%) | 0.853 |
Medication use | |||||
Atorvastatin therapy, n (%) | 124 (72.9%) | 118 (72.8%) | 114 (69.5%) | 122 (77.7%) | 0.427 |
PAMBA therapy, n (%) | 40 (23.5%) | 45 (27.8%) | 53 (32.3%) | 51 (32.5%) | 0.222 |
Hematoma location | 0.367 | ||||
Unilateral left, n (%) | 68 (40.0%) | 82 (50.6%) | 75 (45.7%) | 63 (40.1%) | |
Unilateral right, n (%) | 62 (36.5%) | 48 (29.6%) | 55 (33.5%) | 51 (32.5%) | |
Bilateral, n (%) | 40 (23.5%) | 32 (19.8%) | 34 (20.7%) | 43 (27.4%) | |
GOS at discharge | 0.042 | ||||
5, n (%) | 160 (94.1%) | 149 (92.0%) | 152 (92.7%) | 132 (84.1%) | |
4, n (%) | 8 (4.7%) | 10 (6.2%) | 8 (4.9%) | 22 (14%) | |
3, n (%) | 2 (1.2%) | 3 (1.9%) | 4 (2.4%) | 3 (1.9%) | |